Quince Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Quince Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 02 Nov 2021 | Lorem |
| LoA Update: Cortexyme’s atuzaginstat flops in regulatory chances in Alzheimer’s disease after Phase II/III fail | 02 Nov 2021 | William Newton |
| Novosteo to start CRO hunt for Phase II bone fracture trial of anabolic peptide asset in June; CRO Novotech in charge of Phase I trial, CEO says | 08 Mar 2021 | Sean Rai-Roche |
| Beta amyloid failures in Alzheimer’s suggest combination with drugs for underexplored targets as best path forward, experts say (Clarification) | 08 Aug 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer